ReviewInternational journal of immunopathology and pharmacology
A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies.
Review in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Mathematical models for dengue fever epidemiology: A 10-year systematic review.Physics of life reviews · 2022Pooled it
- Heterologous saRNA prime - multivalent protein boost strategy induces broad and durable immunity against SARS-CoV-2 and MERS-CoV.Scientific reports · 2026Article
- Antibodies Against SARS-CoV-2 Nucleocapsid Protein Possess Autoimmune Properties.Antibodies (Basel, Switzerland) · 2025Article
- Virus-Induced Pathogenic Antibodies: Lessons from Long COVID and Dengue Hemorrhage Fever.International journal of molecular sciences · 2025Review
- Antibody-dependent enhancement of coronaviruses.International journal of biological sciences · 2025Review
- A Comprehensive Review of mRNA-based Vaccines for COVID-19, A New Era in Pharmaceuticals: Unspecified and Unknown Aspects, Effects and Challenges.Current topics in medicinal chemistry · 2025Review
- Influence of previous COVID-19 exposure and vaccine type (CoronaVac, ChAdOx1 nCov-19 or BNT162b2) on antibody and cytokine (Th1 or Th2) responses.Human vaccines & immunotherapeutics · 2024Article
- Parameter identifiability of a within-host SARS-CoV-2 epidemic model.Infectious Disease Modelling · 2024Article
- Fit-for-purpose heterodivalent single-domain antibody for gastrointestinal targeting of toxin B from Clostridium difficile.Protein science : a publication of the Protein Society · 2024Article
- Pathophysiological, immunological, and inflammatory features of long COVID.Frontiers in immunology · 2024Review
- The Therapeutic Monoclonal Antibody Bamlanivimab Does Not Enhance SARS-CoV-2 Infection by FcR-Mediated Mechanisms.Pathogens (Basel, Switzerland) · 2023Article
- Article
- In Vitro Antibody-Dependent Enhancement of SARS-CoV-2 Infection Could Be Abolished by Adding Human IgG.Pathogens (Basel, Switzerland) · 2023Article
- Review
- Genetic Regulation of Interleukin-6 and Interleukin-10 in COVID-19 Infection.Reports of biochemistry & molecular biology · 2023Article
- Article
- Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies.Viruses · 2023Article
- Design of a chimeric ACE-2/Fc-silent fusion protein with ultrahigh affinity and neutralizing capacity for SARS-CoV-2 variants.Antibody therapeutics · 2023Article
- Review
- High viral loads: what drives fatal cases of COVID-19 in vaccinees? - an autopsy study.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents an unprecedented global public health emergency with economic and social consequences. One of the main concerns in the development of vaccines is the antibody-dependent enhancement phenomenon, better known as ADE. In this review, we provide an overview of SARS-CoV-2 infection as well as the immune response generated by the host. On the bases of this principle, we also describe what is known about the ADE phenomenon in various viral infections and its possible role as a limiting factor in the development of new vaccines and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.